Open access
Sep 2026
Development and internal validation of prognostic nomograms for overall and breast cancer-specific survival in de novo stage IV HER2-positive breast cancer.
The nomograms showed good internal discrimination and may support individualized prognostic assessment once initial treatment information is available, and 5-year estimates should be interpreted cautiously given the median follow-up of 27 months.
Xiao-Jie Yu, De-Yuan Fu, L. Yao
· Biomolecules & biomedicine · 0 citations